Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is a leading next-generation sequencing company with a strong and diverse global presence and a potential market value of $40B. Their AI-driven platform is widely used by hospitals and laboratories, and they have a promising partnership with Memorial Sloan Kettering and a new partnership with Mayo Clinic. Despite potential risks, the strong demand for their platform and collaborations in the biopharma industry make SOPHiA's stock a promising investment for future growth.

Bears say

Sophia Genetics is facing several risks that may negatively impact its future performance and profitability. These risks include strong competition in the precision oncology diagnostics market, legal and intellectual property issues, and potential cybersecurity breaches. Additionally, while the company is experiencing growth in its biopharma segment, it still represents less than 10% of total revenue and faces uncertainties surrounding its partnerships with major pharmaceutical companies. Despite its positive outlook on revenue growth and potential profitability in the future, the company's lack of current profitability and uncertainty surrounding its key partnerships makes it a risky investment.

SOPH has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 3 analysts, SOPH has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.